Clinical ResearchInterventional CardiologyImprovement in Mortality Risk Prediction After Percutaneous Coronary Intervention Through the Addition of a “Compassionate Use” Variable to the National Cardiovascular Data Registry CathPCI Dataset: A Study From the Massachusetts Angioplasty Registry
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Resnic was supported, in part, by the National Library of Medicine (grant NIH R01-LM008142); has received research funding support from The Medicines Company; and has received modest consulting support from St. Jude Medical, Medtronic, and Agfa Medical Imaging. The work of Dr. Normand, Ann Lovett, and Katya Zelevinsky was supported through a contract with the Department of Public Health of the Commonwealth of Massachusetts (620022A624PRE). Dr. Normand is the principle investigator of Mass-DAC; receives modest consulting income from Kaiser Permamente, the Institute of Clinical Evaluative Sciences, American Heart Association, St. Luke's Hospital System, The Medicines Company, Best Practices Project Management, Ingenix Inc.; and receives significant support from Yale Medical School. Ms. Zelevinsky reports being employed (50%) by Mass-DAC, the sponsoring research organization for this study. Dr. Ho receives moderate consulting support as a member of an independent clinical events committee administered by the Harvard Clinical Research Institute that provides adjudication services for patients enrolled in clinical trials sponsored by Boston Scientific. All other authors have reported that they have no relationships to disclose.